How to Get Ozempic in Australia: Prescription, PBS Coverage, and Pricing (2026)

TL;DR: Ozempic is available in Australia by prescription from any GP or specialist. It's PBS-subsidised at $25 per script ($6.60 for concession holders) for type 2 diabetes, but not for weight loss. Private prescriptions cost $130 to $220 per month. Wegovy (higher-dose semaglutide, approved for weight management) costs $350 to $450 per month privately, with PBS subsidisation in progress for patients with cardiovascular disease and a BMI of 35 or above. Mounjaro is TGA-approved for both diabetes and weight management but also requires a private prescription ($279+ per pen). The Ozempic supply shortage is over as of mid-2025. Compounded semaglutide has been banned since October 2024.

Ozempic has been one of the most talked-about medications in Australia since supply shortages made national headlines in 2022. Three years later, the supply issues are resolved, the regulatory landscape has shifted, and new options (including a potential PBS-subsidised Wegovy) are on the horizon.

If you're trying to figure out how to actually get semaglutide in Australia right now, whether for diabetes or weight management, this guide covers every pathway: who can prescribe, what it costs with and without PBS, which telehealth platforms are operating in this space, and what's changing in 2026.

What's Approved and What's Not

Australia's Therapeutic Goods Administration (TGA) has approved several GLP-1 medications. Each has different approved indications, which matters because it determines whether PBS subsidy is available.

| Medication | Active Ingredient | TGA-Approved For | PBS Status | |---|---|---|---| | Ozempic | Semaglutide (1mg max) | Type 2 diabetes | PBS-listed for T2D only | | Wegovy | Semaglutide (2.4mg) | Chronic weight management | PBS listing in negotiation (2026) | | Mounjaro | Tirzepatide | T2D and weight management | Not PBS-listed | | Saxenda | Liraglutide (3mg daily) | Chronic weight management | Not PBS-listed | | Contrave | Naltrexone/bupropion | Chronic weight management | Not PBS-listed | | Xenical | Orlistat | Weight management | Available OTC |

The critical distinction: Ozempic is approved by the TGA specifically for type 2 diabetes, and its PBS listing reflects that. Wegovy contains the same active ingredient (semaglutide) at a higher dose and is specifically approved for weight management. They're pharmacologically similar but treated as separate products with separate regulatory pathways.

For a full explanation of how semaglutide, tirzepatide, and liraglutide compare, see the four main GLP-1 drugs explained.

Getting Ozempic for Type 2 Diabetes (PBS Pathway)

If you have type 2 diabetes, Ozempic is accessible and affordable through the PBS.

Who Can Prescribe

Any registered Australian GP can prescribe Ozempic. You don't need a specialist referral. Your GP will assess whether Ozempic is appropriate based on your diabetes management history, specifically whether blood sugar targets haven't been met with metformin alone.

Specialists including endocrinologists and diabetologists also prescribe, but a GP is the most common and accessible route.

PBS Eligibility Criteria

To receive PBS-subsidised Ozempic, you must:

• Have a confirmed diagnosis of type 2 diabetes
• Have inadequate glycaemic control despite an adequate trial of metformin (unless metformin is contraindicated or not tolerated)
• The prescribing doctor must document this in the PBS authority request

What You'll Pay

| Patient Category | Cost Per Prescription | |---|---| | General patients | $25.00 AUD | | Concession card holders | $6.60 AUD | | Safety Net threshold reached | Reduced or free |

Each prescription covers a one-month supply (one pre-filled pen with four weekly doses). At $25 per month, annual costs are $300 AUD, making this one of the most affordable ways to access semaglutide anywhere in the world. For comparison, the same drug costs roughly $900 to $1,000 USD per month in the United States without insurance. See how much Ozempic costs per month for the full US breakdown.

Where to Fill Your Prescription

Ozempic is available at any community pharmacy in Australia. Major chains including Chemist Warehouse, Priceline Pharmacy, and TerryWhite Chemmart stock it. After the supply shortages of 2022 to 2025, Novo Nordisk confirmed in July 2025 that supply has "improved sufficiently to allow normal prescribing for the approved indication." Some individual pharmacies may still have occasional stock variability, but the nationwide shortage is resolved.

If your regular pharmacy is out of stock, they can contact their wholesaler directly, or you can call Novo Nordisk's Australian support line at 1800 668 626.

Note on the pen change: Novo Nordisk is transitioning from the 1.5mL Ozempic pen to a new 3mL pen. The older format is being phased out, with the 1.5mL pen available for dispensing (but no longer new prescribing) until June 1, 2026.

Getting Semaglutide for Weight Loss (Private Pathway)

This is where it gets more expensive and more complicated. If you want semaglutide for weight management (and you don't have type 2 diabetes), there's no PBS subsidy available today. You have two main options: Wegovy through a private prescription, or off-label Ozempic through a private prescription.

Option 1: Wegovy (Private Prescription)

Wegovy is the TGA-approved semaglutide product specifically for chronic weight management. It uses the same active ingredient as Ozempic but at higher doses (up to 2.4mg weekly, compared to Ozempic's maximum 1mg).

Who's eligible: Adults with a BMI of 30 or above (obesity), or a BMI of 27 or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or cardiovascular disease.

Cost: $350 to $450 per month ($4,200 to $5,400 per year) at Australian pharmacies. The starter dose (0.25mg) is at the lower end; the maintenance dose (2.4mg) is at the higher end.

Prescription pathway: Any GP can prescribe Wegovy. Before starting treatment, your GP should conduct a comprehensive obesity assessment including BMI, waist circumference, blood pressure, HbA1c, lipids, liver function, and sleep apnoea screening. They should also establish that you've attempted behavioural interventions (diet, exercise, sleep hygiene) before initiating medication.

Option 2: Off-Label Ozempic (Private Prescription)

Some doctors prescribe Ozempic off-label for weight loss. Because Ozempic's maximum dose is 1mg (versus Wegovy's 2.4mg), it's a lower-dose semaglutide option. Off-label prescribing is legal in Australia, but the medication won't be PBS-subsidised. You'll pay the full private price.

Cost: $130 to $220 per month, depending on dose strength.

Important context: During the 2022 to 2025 shortage, the TGA explicitly asked doctors to stop initiating new patients on semaglutide for off-label uses. Hundreds of doctors received warnings for prescribing PBS-subsidised Ozempic to patients without diabetes. Now that supply has normalised and the shortage is over, off-label prescribing is no longer discouraged for supply reasons. The normal rules of clinical judgment and informed consent apply.

The Wegovy PBS Listing: What's Coming

On January 10, 2026, Health Minister Mark Butler confirmed that the government is negotiating Wegovy's PBS listing with Novo Nordisk following a PBAC (Pharmaceutical Benefits Advisory Committee) recommendation.

The initial PBS listing will be narrowly targeted:

• Established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease)
• BMI of 35 kg/m² or higher (32.5 kg/m² for Asian, Aboriginal, and Torres Strait Islander patients)

Once listed, eligible patients would pay $25 per script (general) or $7.70 per script (concession), the same structure as other PBS medications.

No specific listing date has been announced. Price negotiations between the government and Novo Nordisk are ongoing. The PBAC has recommended a "slow and managed" rollout, acknowledging that broader coverage would create "a very big bill for taxpayers."

The initial eligibility criteria are restrictive. Most Australians seeking semaglutide purely for weight management (without cardiovascular disease) won't qualify for this first phase of PBS access. Broader coverage, if it comes, would follow in later phases.

Mounjaro: The Other Option

Mounjaro (tirzepatide) is TGA-approved for both type 2 diabetes and chronic weight management. It works on two receptors (GIP and GLP-1) rather than just GLP-1, and clinical trials showed it produces somewhat greater average weight loss than semaglutide at equivalent doses.

PBS status: Not listed. The PBAC issued a "Not Recommended" decision in November 2024 for PBS listing. This means Mounjaro is available only through private prescription at full cost.

Cost: From $279 per pen (private prescription). Monthly costs depend on dose and vary by pharmacy.

Who can prescribe: Any GP or specialist. Like Wegovy, it's a Schedule 4 prescription-only medication.

If you're comparing semaglutide and tirzepatide, see the four main GLP-1 drugs explained for a head-to-head analysis.

Telehealth and Online Prescribers

Several Australian telehealth platforms prescribe GLP-1 medications for weight management. This is a growing and controversial segment of the market.

Major Platforms

Juniper (operated by Eucalyptus Health): Australia's largest online weight loss service, focused on women. Offers semaglutide and tirzepatide prescriptions through online consultations reviewed by GPs. Has served over 200,000 Australian women. Also operates in the UK, Japan, and Germany.

Pilot (also Eucalyptus Health): Targets men's health including weight management, with over 100,000 patients.

Rosemary Health: Telehealth weight loss consultations with AHPRA-registered practitioners. Offers prescription medication alongside dietitian support.

What to Know Before Using Telehealth

Telehealth GLP-1 prescribing is a legitimate pathway in Australia, but the quality of clinical assessment varies significantly between providers. Some important considerations:

Regulatory scrutiny is increasing. The Royal Australian College of General Practitioners (RACGP) and the Medical Board have raised concerns about "tick and flick" asynchronous consultation models, where patients complete an online questionnaire reviewed by a doctor without a real-time consultation. In February 2026, ABC News reported a case where a woman was hospitalised with an eating disorder after a telehealth provider prescribed weight loss medication that her long-time GP had refused due to her documented eating disorder history.

Ask about the consultation process. A quality telehealth provider should conduct a video or phone consultation (at minimum for first-time patients), review your medical history thoroughly, screen for contraindications including eating disorders and mental health conditions, and explain the dose titration schedule and expected side effects.

Pricing varies. Telehealth platforms often bundle medication costs with consultation fees and ongoing monitoring, making it difficult to compare directly with pharmacy-only pricing.

Your GP is still an option. If you have an established relationship with a GP who knows your medical history, that's often the safer starting point. They can prescribe Wegovy or off-label Ozempic for weight management just as readily as any telehealth platform can.

Compounding: Banned in Australia

Unlike the United States, where compounding pharmacies have been a significant source of cheaper semaglutide, compounded semaglutide has been banned in Australia since October 1, 2024.

The TGA amended the Therapeutic Goods Regulations to remove GLP-1 receptor agonist products from the pharmacist compounding exemption. The reasons:

• Compounded semaglutide products hadn't undergone TGA evaluation for safety, quality, and efficacy
• Telehealth providers were increasingly offering these unapproved products
• Sterile injectables compounded outside regulated manufacturing facilities carry contamination and dosing risks

Novo Nordisk does not supply semaglutide to compounding pharmacies and does not support compounded products.

If you see a clinic or online service advertising compounded semaglutide in Australia, that's a red flag. It's also worth noting that advertising any prescription GLP-1 medication directly to consumers is illegal under the Therapeutic Goods Act and can result in criminal or civil penalties.

What's on the Horizon

Beyond the Wegovy PBS listing, several developments could change the Australian GLP-1 landscape in 2026 and beyond:

Oral semaglutide: An oral formulation of semaglutide (Rybelsus) is already TGA-approved for type 2 diabetes. A higher-dose oral formulation for weight management could follow the global pipeline.

Orforglipron (Eli Lilly): An oral GLP-1 drug under TGA evaluation as of early 2026. Clinical trials showed strong weight loss results, and Eli Lilly is targeting availability as early as Q2 2026. An effective oral option would eliminate the injection barrier that puts some patients off GLP-1 therapy.

Broader PBS coverage: The PBAC has signalled a phased approach to GLP-1 subsidy, starting with high-risk cardiovascular patients. Future phases could expand to patients requiring weight loss for surgical eligibility, patients with medication-induced obesity, and Aboriginal and Torres Strait Islander patients with obesity-related comorbidities. Broader general obesity coverage, though, may require a separate funding program outside the traditional PBS structure.

Generic semaglutide (eventually): Australia's patent timeline for semaglutide extends further than Canada or India, where generics are already launching or imminent. For a look at what generic competition looks like when it arrives, see generic semaglutide in India, where prices dropped 70% to 90% within weeks of patent expiry.

A Practical Checklist

If you're an Australian looking to start semaglutide, here's the decision tree:

Do you have type 2 diabetes? Your GP can prescribe PBS-subsidised Ozempic at $25 per script. Start here.

Do you have cardiovascular disease and a BMI of 35+? Watch for the Wegovy PBS listing. When it goes live, your GP can prescribe it at $25 per script. In the meantime, your GP can prescribe Wegovy privately ($350 to $450/month).

Do you want semaglutide for weight management without the above conditions? You'll need a private prescription. Options: Wegovy ($350 to $450/month), off-label Ozempic ($130 to $220/month), or Mounjaro ($279+/month). See your GP or a telehealth provider.

Can you afford $130 to $450 per month? If not, Contrave (oral, prescription) and Xenical (OTC, ~$120/month) are less expensive TGA-approved weight loss medications, though with more modest efficacy. For a broader look at approaches including non-pharmaceutical options, see the best weight loss peptides ranked by evidence.

Whatever pathway you take, semaglutide works best as part of a broader approach that includes dietary changes, physical activity, and understanding the behavioural patterns that make sustained weight loss difficult. For the psychological side of that equation, why diets fail at the psychological level is worth reading.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication, including semaglutide. Pricing, PBS eligibility, and drug availability are subject to change. For the latest PBS listings, visit pbs.gov.au.

Ready to stop fighting your cravings and start reprogramming your mind for lasting success? The Hypna AI 21-day self-hypnosis program is designed to help you rewire subconscious patterns and build a healthier relationship with food from the inside out.